Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Journal:

Journal of Clinical Oncology

Published:

2026-03-13

DOI:

10.1200/jco-25-00570

Affiliations:

21

Authors:

175

Go to article

Institutions	Authors	Share
non-affiliated author contributions, United States of America (USA)	158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333 158.833333	0.91
Merck - Rahway, United States of America (USA)	3.000000	0.02
Hetényi Géza Kórház, Hungary	1.000000	0.01
Centre Léon Bérard (CLB), France	1.000000	0.01
Eisai Inc., United States of America (USA)	1.000000	0.01
A.C. Camargo Cancer Center (CIPE), Brazil	1.000000	0.01
National Institute of Neoplastic Diseases (INEN), Peru	1.000000	0.01
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.01
Eisai Limited, United Kingdom (UK)	1.000000	0.01
University of Michigan (U-M), United States of America (USA)	1.000000	0.01
Institute Gustave-Roussy (IGR), France	0.500000	0.00
Shanghai East Hospital, Tongji University, China	0.500000	0.00
Hacettepe University, Turkey	0.500000	0.00
Yaroslavl Region Clinical Oncology Hospital, Russia	0.500000	0.00
Cancer Institute Hospital, JFCR, Japan	0.500000	0.00
Zhejiang Cancer Hospital (ZJCH), China	0.500000	0.00
The Royal Marsden NHS Foundation Trust, United Kingdom (UK)	0.500000	0.00
National Cancer Center Hospital East, Japan	0.500000	0.00
Taipei Veterans General Hospital (TPEVGH), Taiwan	0.500000	0.00
University of Milan (UNIMI), Italy	0.333333	0.00
IRCCS National Cancer Institute (INT) Milan, Italy	0.333333	0.00

Interested in Oncology and Carcinogenesis?